EMA Authorised: Potactasol (topotecan) — Actavis Group PTC ehf

View source ↗

Summary

The EMA has authorised Potactasol (topotecan) for cervical cancer and small cell lung cancer, with Actavis Group PTC ehf as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Potactasol (topotecan)

Snippet

Status: Authorised. Therapeutic area: Uterine Cervical Neoplasms;Small Cell Lung Carcinoma. MAH: Actavis Group PTC ehf. Decision date: 17/01/2025